Inspire Medical Systems Analysts Lower Their Forecasts After Q2 Results
1. INSP reported Q2 earnings of $0.45, surpassing estimates of $0.21. 2. Company lowered FY2025 EPS guidance significantly to $0.40-$0.50. 3. Sales guidance for FY2025 reduced to $900 million-$910 million. 4. Analysts have downgraded price targets for INSP following disappointing guidance. 5. Shares fell 40.6% to $77.14 after the announcement.